For colorectal cancer patients with type II diabetes, could metformin improve the survival rate? A meta-analysis - 29/01/20
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 9 |
| Iconographies | 4 |
| Vidéos | 0 |
| Autres | 0 |
Highlights |
• | A systemic evaluation of metformin using and colorectal cancer survival. |
• | Patients with colorectal cancer who have long-term use of metformin have an overall improvement in overall survival. |
• | BMI does not affect the anticancer effect of metformin. |
Summary |
Objective |
Current research is controversial about whether metformin can improve the survival rate of patients with colon cancer. Therefore, we conducted a meta-analysis to identify the association between metformin and the survival rate of colorectal cancer (CRC) patients with type II diabetes.
Methods |
We conducted a search in databases including Pubmed, EMBASE and Cochrane Library. All articles were published in the last decade, and the quality of each study was evaluated by the Newcastle-Ottawa Scale. Odds ratios (ORs) and its corresponding 95% confidence intervals (CIs) for each study were calculated and summary relative risk estimates with corresponding 95% CIs were generated using the random-effects model. Heterogeneity and publication bias were assessed.
Results |
Ten articles were included in this meta-analysis. The included articles were all cohort studies. In a pooled analysis of all studies, metformin using was associated with increased overall survival (OS) rate (OR, 0.54; 95% CI, 0.47 to 0.63) and cancer-specific survival (CS) rate (OR 0.59; 95% CI 0.43 to 0.82) of CRC patients with diabetes. We found that the effect of metformin is associated with geographical region through subgroup meta-analysis.
Conclusions |
Metformin using was associated with an increased OS rate and CS rate of colorectal cancer.
Le texte complet de cet article est disponible en PDF.Keywords : Colorectal cancer, Metformin, Diabetes, Overall survival
Plan
Vol 44 - N° 1
P. 73-81 - février 2020 Retour au numéro
Article précédent
- B-cell depletion induces prolonged remission in patients with giant cell hepatitis and autoimmune hemolytic anemia
- Lorenza Matarazzo, Teresa Di Chio, Silvia Nastasio, Alberto Tommasini, Alessando Ventura, Giuseppe Maggiore
- Per-oral endoscopic myotomy for esophageal diverticula with or without esophageal motility disorders
- Beatrice Orlandini, Maximilien Barret, Marie-Anne Guillaumot, Chloé Léandri, Sarah Leblanc, Frédéric Prat, Stanislas Chaussade
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?